OOIR: Observatory of International Research

Papers

(The TQCC of JCO Precision Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer	57
Pyroptosis-Derived Long Noncoding RNA Profiles Reveal a Novel Signature for Evaluating the Prognosis of Patients With Lung Adenocarcinoma	55
TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence	52
Abscopal Effect of Radiation on Liver Metastases of Poorly Differentiated Parotid Carcinoma	50
Role of Apparent Diffusion Coefficient Map-Based First- and High-Order Radiomic Features for the Discrimination of Sacral Chordomas and Chondrosarcomas With Overlapping Conventional Imaging Features	48
Progression of Mycosis Fungoides After Fingolimod Treatment for Multiple Sclerosis and Targeted Next-Generation Sequencing Demonstrating Potential Links Between the Two Diseases	46
Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Explora	42
Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer	42
Reply to H. Seibert et al	41
Novel OncogenicPDGFRBVariant in Severe Infantile Myofibromatosis With Response to Imatinib Using Therapeutic Drug Monitoring	39
BRCA1/2Variants Identified Through Tumor Genomic Profiling: Assessing Genetic Counseling Outcomes	39
Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function	38
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma	38
Novel Adjuvant Targeted Approach for PTEN-Mutated Choroid Plexus Carcinoma in Adults: Case Report and Literature Review	35
Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary	35
Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non–Small-Cell Lung Cancer	35
Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer	34
Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome	34
Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience	34
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy	33
Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies	33
Clinical Trial Diversity: A Bend in the Arc Toward Justice	32
Nodular Regenerative Hyperplasia of the Liver Associated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor in a Patient With Metastatic Renal Cell Carcinoma	32
Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMI	31
Germline Pathogenic Variants in Patients With Pancreatic and Periampullary Cancers	31

Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma	30
Dabrafenib for Pilocytic Astrocytoma With BRAF V599ins	30
Venetoclax and Azacitidine in the Treatment of NPM1-Mutated Donor Cell–Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review	29
Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study	29
Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project	28
Targeted Therapies in Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids on the Block	27
High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content	26
GermlineSMARCA4Deletion as a Driver of Uterine Cancer: An Atypical Presentation	26
About RAS Mutation Clearance in Plasma ctDNA From RAS-Mutant Colorectal Cancer Patients	26
Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo-RAS-Wildtype Metastatic Col	26
Association of RNF43 Genetic Alterations With BRAF^V600E and MSI^high in Colorectal Cancer	25
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies	24
Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel IntergenicANK3-RETFusion inEGFR-Mutated Non–Small-Cell Lung Cancer	24
Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer	23
Peritoneal Tumor DNA as a Prognostic Biomarker in Gastric Cancer: A Systematic Review and Meta-Analysis	23
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit	23
MEK Inhibition in a Pilocytic Astrocytoma With a Rare KRAS Q61R Mutation in a Young Adult Patient: A Case Report	22
Reply to S. Cavalieri et al	22
Reply to S. Li et al	22
Renal Cell Carcinoma With Urinary Bladder Metastasis: A Case Report With Metachronous Genomic Analyses	22
Treatment of Disseminated Intravenous Leiomyomatosis With ALK Targeting Crizotinib: A Successful Case Report	21
Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression—A Case Report	21
CDK4/6 Inhibition With Anti–PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD–1 Alone	21
Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B	20
Response to PD-1 Immunotherapy in Metastatic Spiradenocarcinoma	20
Timing and Ideal Patient for an Appropriate Search for Somatic RET Mutation in Medullary Thyroid Cancer	20
An Old but Still Unanswered Question in Recurrent or Metastatic Salivary Duct Carcinoma	20
Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy	19
Use of Neoadjuvant Vandetanib in Aggressive Pediatric Medullary Thyroid Carcinoma	19
Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion–Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting	19
Early Presentation of Homozygous Mismatch Repair Deficient Glioblastoma in Teen With Lynch Syndrome: Implications for Treatment and Surveillance	18
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Receiving Palbociclib: Results From th	18
Using Artificial Intelligence to Support Informed Decision-Making on BRAF Mutation Testing	18
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors	18
Fully Automated Artificial Intelligence Solution for Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Scoring in Breast Cancer: A Multireader Study	18
Targeting All BRAF Alterations: The (Re)-Search Continues	18
Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion–Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?	17
Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine	17
Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an	17
Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab	17
Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient WithETV6-NTRK3Fusion-Positive Carcinoma Harboring theNTRK3^G623RSolvent-Front Mutation	16
Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase	16
Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care	16
Comprehensive Genomic Analysis of Patients With Non–Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan	15
Clearance Profile of Circulating Tumor Human Papillomavirus DNA During Radiotherapy Predicts Clinical Outcomes in Human Papillomavirus–Related Oropharyngeal Cancer	15
Cancer Risk Associated With PTEN Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel Testing	15
Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2–Positive Advanced Gastric Cancer	15
Isolated MLH1 Loss by Immunohistochemistry Because of Benign Germline MLH1 Polymorphisms	15
Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2	14
ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready?	14

Outcomes of the IMMray PanCan-d Test in High-Risk Individuals Undergoing Pancreatic Surveillance: Pragmatic Data and Lessons Learned	14
Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set	14
Improving Prediction of Survival and Progression in Metastatic Non–Small Cell Lung Cancer After Immunotherapy Through Machine Learning of Circulating Tumor DNA	14
Complete Response to Sequential Human Epidermal Growth Factor Receptor 2–Targeted Strategies in a Heavily Pretreated Patient With Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Bladder	14
Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study	14
Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study	14
Consensus Statements on Precision Oncology in the China Greater Bay Area	14
Differential Impact of ALK Mutations in Neuroblastoma	13
Spontaneous Immune-Mediated Regression of Hepatocellular Carcinoma With High Tumor Mutational Burden	13
Polygenic Breast Cancer Risk for Women Veterans in the Million Veteran Program	13
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors	13
Rate of Pathogenic Germline Variants in Patients With Lung Cancer	13
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations	13
Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS ^G12C -Mutated Non–Small Cell Lung Cancer: A Case Series and Liter	13
Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates	13
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers	13
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics	13
Erratum: Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS ^G12C -Mutated Non–Small Cell Lung Cancer: A Case Series	13
Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs	12
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's	12
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers	12
Insights for Quantifying the Long-Term Benefit of Immunotherapy Using Quantile Regression	12
Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline BRCA1/2-Mutated Breast Cancers in the High-Risk, Early-Stage Setting	12
Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With ROS1-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort Study	12
Comparing the Diagnostic Yield of Germline Exome Versus Panel Sequencing in the Diverse Population of the Texas KidsCanSeq Pediatric Cancer Study	12
Clinical Utility of Molecular Tumor Board Review for Identification of Possible Germline Pathogenic Variants on Tumor Next-Generation Sequencing Reports	12
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer	12
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas	12
Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing	11
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study	11
Parent Quality of Life After Disclosure of Pediatric Oncology Germline Sequencing Results	11
Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma: A Translocation-Associated Sarcoma	11
Small Cell Transformation in a Patient With RET Fusion–Positive Lung Adenocarcinoma on Pralsetinib	11
Diagnostic Yield From a Nationwide Implementation of Precision Medicine for all Children With Cancer	11
DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance	11
Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine	11
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes	11
Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies	11
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to ¹⁷⁷Lu-PSMA-617: A Retrospective Multicenter Cohort Study	11
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy	11
Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome	11
Optimized Detection of Unknown MET Exon 14 Skipping Mutations in Routine Testing for Patients With Non–Small-Cell Lung Cancer	11
Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma	11
Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung Cancer	11
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer	11
Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like–Induced Protein Changes in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Throughout Disease Progr	11
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care	11
Tumor Mutations Across Racial Groups in a Real-World Data Registry	10
Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults	10
Loss of SNAI2 in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy	10
Erratum	10
Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types	10
Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based Therapy	10
Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases	10
Sustained Response to the Mitogen-Activated Extracellular Kinase Inhibitor Trametinib in a Spindle Cell Sarcoma Harboring a QKI-RAF1 Gene Fusion	10
Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments	10
Erratum	10
Erratum	10
Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis	10
Erratum: Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study	10
Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer	10
Response to BRAF and MEK Inhibitors in BRAF Thr599dup–Mutated Melanoma	10
Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion	10
GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer–Specific Mortality	10
Sustained Response to Brigatinib in an Aggressive Relapsing Atypical Pituicytoma With ELM4-ALK Fusion	10
Erratum: Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study	10
Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy	10
Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal Melanoma	9
Circulating Cell-Free DNA Captures the Intratumor Heterogeneity in Multinodular Hepatocellular Carcinoma	9
Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Sp	9
Erratum: Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy	9
Erratum: Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants	9
Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts	9
Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases	9
Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma	9
Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung Cancers	9
Identification of a Suitable Subgroup for Radiation Dose Escalation in Definitive Concurrent Chemoradiation Therapy for Nonmetastatic Esophageal Squamous Cell Carcinoma	9
Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis	9
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2–Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Orga	9
Differential Activity of PARP Inhibitors inBRCA1- VersusBRCA2-Altered Metastatic Castration-Resistant Prostate Cancer	9

Prospective Characterization of Circulating Tumor Cell Kinetics in Patients With Oligometastatic Disease Receiving Definitive Intent Radiation Therapy	9
Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study	9
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers	9
Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors	9
Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants	9
Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Rand	9
Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors	9
Fatal Intracranial Hemorrhage With Belzutifan in von Hippel-Lindau Disease–Associated Hemangioblastoma: A Case Report	9
Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations	8
CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer	8
DPYD7* as a Predictor of Severe Fluoropyrimidine-Related Adverse Events	8
Clinical Utility of Functional Precision Medicine in the Management of Recurrent/Relapsed Childhood Rhabdomyosarcoma	8
Acknowledgment of Reviewers, 2022	8
Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?	8
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers	8
BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma	8
Soft Tissue Leiomyosarcoma With Microsatellite Instability, High Tumor Mutational Burden, and Programmed Death Ligand-1 Expression Showing Pathologic Complete Response to Pembrolizumab: A Case Report	8
Patient Experience of Complex Genomic Sequencing Exploring Patient Preference, Barriers, and Enablers for Delivery	8
Efficacy of Trastuzumab Deruxtecan in a Patient With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer With Acute Intracranial Hypertension Because of Brain Metastases	8
Improved Cancer-Specific Risk Stratification by the Lymph Node Ratio-Based Nomogram: A Potential Role in Guiding Postoperative Management Decisions for Oral Cavity Carcinoma	8
Rapid Breakpoint Mapping of a Novel Germline PALB2 Duplication by PCR-Free Long-Read Sequencing for Interpretation of Its Pathogenicity	8
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report	8
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Tumors That Reclassify as Basal-Type	8
Reply to M. Younes	8
Lung Cancer in Li-Fraumeni Syndrome	8
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study	8
TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer	8
Early Completion of Model-Assisted Designs for Dose-Finding Trials	7
Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention	7
Response to Alpelisib in an Adolescent With PIK3CA-Mutated Metastatic Gastrointestinal Stromal Tumor	7
Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer	7
Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma	7
Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion	7
Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology	7
High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency–Associated Genomic Instability in Ovarian Cancer	7
Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer	7
Reply to A. Rizzo et al	7
Acknowledgment of Reviewers, 2023	7
Divergent RET- and BRAF-Mediated Resistance to Osimertinib in EGFR-Mutant NSCLC: A Case Report	7
Common Variant in ALDH2 Modifies the Risk of Breast Cancer Among Carriers of the p.K3326* Variant in BRCA2	7
Two Germline Pathogenic Variants in Cancer Susceptibility Genes and Their Null Implication in Breast Cancer Pathogenesis: The Importance of Tumoral Homologous Recombination Deficiency Testing	7
Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma	7
Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately	7
Molecular Tumor Board Guides Successful Treatment of a Rare, Locally Aggressive, Uterine Mesenchymal Neoplasm	7
Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia	7
Marked Response to Larotrectinib in Pelvic Spindle Cell Sarcoma With Concurrent TPM3-NTRK1 Fusion and CDK4/MDM2 Amplification: A Case Report	7
Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer	6
Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma	6
Analysis of Breast Cancer Brain Metastases Reveals an Enrichment of Cyclin-Dependent Kinase 12 Structural Rearrangements in Human Epidermal Growth Factor Receptor 2–Positive Disease	6
Safety and Intracranial Activity of Adagrasib in Patients With KRAS^G12C-Mutated Non–Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series	6
Genomic Complexity as a Biomarker to De-Escalate Adjuvant Imatinib Treatment in High-Risk Gastrointestinal Stromal Tumor	6
Blood Test for Multicancer Detection in Symptomatic Individuals	6
Hereditary Cancer Screening and Outcomes at an Urban Safety-Net Hospital	6
RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma	6
Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer	6
Unleashing a Lazarus Effect With Selpercatinib in a Never-Smoker Patient With Stage IV, Chemo-Immunotherapy Refractory, RET C630Y-Mutant, Small-Cell Lung Cancer: A First Case Report	6
TCF3-HLF-Positive Acute Lymphoblastic Leukemia Resembling Burkitt Leukemia: Cell Morphologic and Immunophenotypic Findings	6
Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology Trials	6
Prognostic Significance of Tumor-Infiltrating Lymphocytes Determined Using LinkNet on Colorectal Cancer Pathology Images	6
Different Fumarate Hydratase Gene Variants Are Associated With Distinct Cancer Phenotypes	6
Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer	6
Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non–Small-Cell Lung Cancer From the Perspective of Spanish Reference	6
Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets	6
Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations	6
Acknowledgment of Reviewers, 2021	6
Diagnostic and Practical Challenges in Applying National Comprehensive Cancer Network Guidelines for Suspected Pathogenic TP53 Mosaicism	6
ESR1 Rearrangement as a Diagnostic and Predictive Biomarker in Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Report of Four Cases	6
Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics	6
Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes	6
Donor-Derived Follicular Lymphoma After Kidney Transplantation: A Case Report	6
Therapeutic Strategies for Gliomas Associated With Cancer Predisposition Syndromes	6
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials	6
Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion	6
Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase	6
Efficacy and Safety of Immune Checkpoint Blockade in Patients With Li-Fraumeni Syndrome	6
Urinary 3-Methoxytyramine Is a Biomarker for MYC Activity in Patients With Neuroblastoma	6
Efficacy of Trametinib in Neurofibromatosis Type 1–Associated Gastrointestinal Stromal Tumors: A Case Report	6
Multigene Panel Testing in Individuals With Hepatocellular Carcinoma Identifies Pathogenic Germline Variants	6
Reply to P. Gazzaniga et al	6
Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non–Small-Cell Lung Cancer	6
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer	6
TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing	6
Reply to F. Dayyani et al	6
Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer	6
Clinical Implication of HER2 Aberration in Patients With Metastatic Cancer Using Next-Generation Sequencing: A Pan-Tumor Analysis	6
Reclassfying Estrogen Receptor–Positive/Basal Subtype by Using Immunohistochemistry Itself According to Grade and Estrogen Receptor Positivity Might Be Possible	6
Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review	5
Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group	5
Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer	5
Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF	5
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1	5
PIK3CAMutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer	5
Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors	5
Genome-Scale Multimodal Analysis of Cell-Free DNA Whole-Methylome Sequencing for Noninvasive Esophageal Cancer Detection	5
Clinical Utility of Precision Medicine in Pediatric Oncology: A Systematic Review	5